Ulcerative colitis trials recruiting in Alabama

All Ulcerative colitis trials nationally

Cities in Alabama

Recruiting trials in Alabama

• A Phase 2 Study to Evaluate Therapies for Inflammatory Bowel Disease
  NCT07113522 · Phase: Phase 2 · Ages: 18 Years to 80 Years · Sex: All (male and female) · Alabama: Birmingham
• A Study of Vedolizumab With Tofacitinib in Adults With Ulcerative Colitis (UC)
  NCT06095128 · Phase: Phase 4 · Ages: 18 Years to 65 Years · Sex: All (male and female) · Alabama: Dothan
• A Study of Vedolizumab in Adults With Ulcerative Colitis (UC) or Crohn's Disease (CD) in the Community Setting
  NCT06581328 · Phase: Phase 4 · Ages: 18 Years to 80 Years · Sex: All (male and female) · Alabama: Birmingham, Mobile
• A Study of Vedolizumab in Children With Ulcerative Colitis (UC) or Crohn's Disease (CD)
  NCT05442567 · Phase: Phase 3 · Ages: 2 Years and older · Sex: All (male and female) · Alabama: Mobile
• A Study to Assess the Efficacy and Safety of Induction Therapy With Afimkibart (Also Known as RO7790121) in Participants With Moderately to Severely Active Ulcerative Colitis
  NCT06588855 · Phase: Phase 3 · Ages: 16 Years to 80 Years · Sex: All (male and female) · Alabama: Dothan
• Hyperbaric Oxygen Therapy for Ulcerative Colitis (HBOT-UC)
  NCT05987852 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years to 85 Years · Sex: All (male and female) · Alabama: Birmingham
• Mirikizumab Administered at the Same Time as Tirzepatide in Adult Participants With Moderately to Severely Active Ulcerative Colitis and Obesity or Overweight: Phase 3b Study
  NCT06937086 · Phase: Phase 3 · Ages: 18 Years to 70 Years · Sex: All (male and female) · Alabama: Dothan
• Study of Advanced Therapies for the Treatment of Adult Participants With Moderately to Severely Active Crohn's Disease or Ulcerative Colitis
  NCT07697456 · Phase: Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female) · Alabama: Dothan
• Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVO
  NCT03816345 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · Alabama: Birmingham